Sirona Biochem's Cosmetic Skin Lighteners More Stable Than Leading Compound, According to New Study
November 29 2012 - 09:00AM
Marketwired
Sirona Biochem Corp. (TSX VENTURE:SBM) announced today its
subsidiary, TFChem, demonstrated stability of its skin depigmenting
agents for cosmetic skin lightening. The company's compounds,
TFC-849 and TFC-723, were more stable than alpha- and beta-arbutin,
two of the world's most popular skin lightening compounds. In
addition, the company's compounds did not release hydroquinone, a
potentially toxic substance linked to many leading skin lighteners.
The study, funded through a $1.9 million French grant, is led by
TFChem and involves a consortium of partners.
View Sirona Biochem Video News Release
"We are addressing a major concern of skin lighteners by
developing an alternative that does not release hydroquinone," said
Neil Belenkie, Chief Executive Officer of Sirona Biochem. "This
study proves that we are on track to producing an effective and
safe skin depigmenting agent that major cosmetic brands are seeking
in their formulations," he added.
Stability of the company's compounds, TFC-849 and TFC-723, was
measured in multiple conditions: chemical (buffer, pH,
temperature), enzymatic (alpha- and beta-glucosidase, enzymes
causing degradation of natural arbutins), and biological (sweat and
skin tissular or cellular extracts). For comparison, alpha- and
beta-arbutin were also tested in the same conditions. In all tested
conditions, Sirona Biochem's compounds were stable and did not
release hydroquinone. However, the study showed both alpha- and
beta-arbutin released hydroquinone.
Further studies to evaluate the company's compounds' safety and
microbial innocuity are ongoing.
In Asia and the United States, hydroquinone is a commonly used
but potentially toxic skin lightening agent. In some cases,
commercial formulations of skin lighteners break down causing the
release of hydroquinone. Safety concerns and adverse events related
to the use of hydroquinone have resulted in the European Union
banning its use and the United States putting restrictions on
allowable hydroquinone concentration levels.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes
therapeutics, cancer vaccine antigens, skin depigmenting and
anti-aging agents for cosmetic use, and biological ingredients. The
company utilizes a proprietary chemistry technique to improve
pharmaceutical properties of carbohydrate-based molecules. For more
information visit www.sironabiochem.com.
About the Project
Sirona Biochem's French subsidiary, TFChem received in November
2011 a $1.9-million grant. This project is co-financed by the
European Union and Europe Witnesses in Haute-Normandie with the
support of the European Regional Development Fund (E.R.D.F.). A
consortium of partners - including the University of Rouen (LMSM
EA4312), contract research organization Biogalenys, and TFChem -
has been assembled to advance this project. The French government
and European Union are looking to promote and initiate
collaborative projects that are focused on the development of new
products and services containing a high level of innovation.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Contacts: Sirona Biochem Corp. Julie Jang Director,
Communications 604.282.6065jjang@sironabiochem.com
www.sironabiochem.com
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Mar 2023 to Mar 2024